Robert Johnson

Robert Johnson has held various roles in the biotech and pharmaceutical industries. Robert'smost recent position is the Chief Executive Officer at Adrestia Therapeutics, where they lead the development of new treatments for genetic diseases. Prior to this, they were the Co-Founder and Head of Business Development at Affinia Therapeutics, where they played a key role in raising funding and advancing gene therapy research. Robert also served as the Chairman of the Board at Foothold America and held leadership positions at Alacrita Consulting, where they built and managed consulting practices in the US and UK. Additionally, they founded and led Foothold America, a company that facilitates the hiring of foreign workers in the US. Throughout their career, Johnson has provided strategic and business development advice to companies such as Debiopharm, BerGenBio ASA, Exscientia, Bristol Myers Squibb, and Immatics.

Robert Johnson attended Oundle School from 1995 to 1999. Robert then pursued a Bachelor of Science degree in Molecular Cell Biology at the University of Nottingham from 1996 to 1999. In 2002 and 2003, they enrolled in the Corporate Finance Evening Programme at the London Business School, focusing on Finance, General.